A new immunotherapy for treating glioblastoma using the patient's own immune cells
Neoantigen-specific Adoptive T Cell Therapy for Glioblastoma, IND-BB-13135, protocol submitted 04/25/2020
This study is testing a new treatment for people recently diagnosed with glioblastoma that uses a personalized vaccine made from their own cancer cells to help their immune system fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tvax Biomedical, INC. NIH-funded |
| Lab location | 1 site (Olathe, United States) |
| Project ID | NIH-10505087 on NIH RePORTER |
What this research studies
This research investigates a novel immunotherapy called neoantigen-specific adoptive T cell therapy (NACT) designed to improve outcomes for patients newly diagnosed with glioblastoma. The approach involves creating a personalized vaccine from the patient's own cancer cells, which is combined with an immunological adjuvant to stimulate a robust immune response. Patients will receive ex vivo-activated T cells that specifically target cancer neoantigens, along with interleukin 2 to enhance the treatment's effectiveness. This method aims to provide a safer and more effective alternative to traditional treatments, particularly for those resistant to standard therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are newly diagnosed glioblastoma patients, particularly those with the MGMT unmethylated subtype who have limited treatment options.
Not a fit: Patients with glioblastoma who are not newly diagnosed or those whose tumors are not surgically resectable may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for glioblastoma patients, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
Olathe, United States
- Tvax Biomedical, INC. — Olathe, United States (Active)
Researchers
- Principal investigator: Wood, Gary W. — Tvax Biomedical, INC.
- Study coordinator: Wood, Gary W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.